Swedish Orphan Biovitrum distributes Novastan in the Nordic region following an agreement with Mitsubishi Pharma Europe.
Novastan is a reversible direct thrombin inhibitor indicated for anticoagulation in adult patients who have developed HIT type II. The onset of Novastan is rapid and the effect can be easily monitored using APTT. Novastan can be given also to patients with all degrees of impaired kidney function, without changing the initial dose. There is no cross reaction with HIT antibodies. Novastan is not immunogenic and the risk of anaphylaxis is low.